Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Centanamycin SCHEMBL29441389 | 1.00 | LMNA (0.46) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5734847 | 0.93 | LMNA (0.46) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5733054 | 0.90 | LMNA (0.47) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL6179609 | 0.90 | LMNA (0.43) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5734826 | 0.85 | KDM4E (0.44) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL6178008 | 0.83 | KDM4E (0.42) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5733051 | 0.81 | LMNA (0.41) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5789593 | 0.80 | LMNA (0.48) | LMNAKDM4EALDH1A1HPGDTP53 | |
| SCHEMBL6178778 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1TP53MAPTHDAC1 | |
| SCHEMBL14234930 | 0.78 | LMNA (0.42) | LMNAKDM4EALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| EP-4694935-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4688871-A1 | SITE-SPEICFIC ORTHOGONAL BIOCONJUGATE MODALITY AND APPLICATION THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250387505-A1 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2025-12-25 | — | — | US | claimed |
| EP-4601702-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| EP-4592311-A2 | ANTIBODIES | Lonza Ltd (CH) | 2025-07-30 | — | — | EP | claimed |
| WO-2022218331-A9 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2025-06-19 | — | — | WO | claimed |
| US-12325755-B2 | Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-10 | — | — | US | claimed |
| WO-2022236370-A1 | IMMUNOGENIC COMPOSITION | GRIFFITH UNIVERSITY (AU) | 2022-11-17 | — | — | WO | claimed |
| WO-2022218331-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-10-20 | — | — | WO | claimed |
| CN-115197297-A | Linker, conjugate and application thereof | 启德医药科技（苏州）有限公司 | 2022-10-18 | — | — | CN | claimed |
| US-11434301-B2 | Anti-CD46 antibodies and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-06 | — | — | US | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| CN-114502200-A | Antibody drug conjugates | 深圳康源久远生物技术有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022093729-A1 | REPLICATION-DEFECTIVE VACCINES AND USES THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-05-05 | — | — | WO | claimed |
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | claimed |
| US-6660742-B2 | Alkylation therapy; anticancer agent | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2003-12-09 | — | — | US | claimed |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | MEDIMMUNE LIMITED (GB) | 2003-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CLTB, DCLRE1A, FCGRT | LMNA 517/4885KDM4E 2047/4885ALDH1A1 2425/4885 |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | PTMS, ACP1, CD2 | LMNA 3725/4885KDM4E 2103/4885ALDH1A1 383/4885 |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | CLTB, LNPEP, DCLRE1A | LMNA 1064/4885KDM4E 2451/4885ALDH1A1 1827/4885 |
| US-20250387505-A1 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | FGFR3, IGSF11, IDUA | LMNA 3483/4885KDM4E 1822/4885ALDH1A1 2376/4885 |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | DDB1, ERCC2, SSU72 | LMNA 1231/4885KDM4E 1215/4885ALDH1A1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.